- Home
- LFT vs IMA Comparison
LFT vs IMA Comparison
Compare LFT & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | IMA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4M | 65.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LFT | IMA |
|---|---|---|
| Price | $1.34 | $7.33 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 234.8K | 30.6K |
| Earning Date | 03-18-2026 | 02-15-2026 |
| Dividend Yield | ★ 11.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $21,708,246.00 | $800,000.00 |
| Revenue This Year | $124.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.23 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.30 | $5.70 |
| 52 Week High | $2.84 | $18.00 |
Technical Indicators
Market Signals| Indicator | LFT | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 58.05 |
| Support Level | $1.44 | $6.93 |
| Resistance Level | $1.46 | $7.40 |
| Average True Range (ATR) | 0.05 | 0.40 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 2.18 | 92.45 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.